Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'

Br J Cancer. 2015 Dec 1;113(11):1635. doi: 10.1038/bjc.2015.325. Epub 2015 Sep 10.

Authors

Andrew Rowland^{1

2}, Mafalda M Dias^{1

3}, Michael D Wiese³, Ganessan Kichenadasse², Ross A McKinnon², Christos S Karapetis², Michael J Sorich^{1

2}

Affiliations

¹ Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
² Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
³ School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.

No abstract available

Publication types

Letter
Comment

MeSH terms

Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics*
ErbB Receptors / antagonists & inhibitors*
Humans
Mutation*
Proto-Oncogene Proteins B-raf / genetics*

Substances

ErbB Receptors
Proto-Oncogene Proteins B-raf